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Abstract 
Background: Emergence of chloroquine resistant Plasmodium vivax is a serious obstacle towards malaria control in 
India. This study elucidates the temporal pattern of antifolate [sulfadoxine–pyrimethamine (SP)] resistance in P. vivax 
infection by means of genetic polymorphisms, especially analysing the single nucleotide polymorphisms of dihy-
drofolate reductase (pvdhfr) and dihydropteroate synthase (pvdhps) gene among the field isolates of urban Kolkata 
Municipal Corporation and rural Purulia region of West Bengal, India.
Methods: Blood samples were collected from 99 microscopically diagnosed P. vivax patients (52 from Kolkata 
Municipal Corporation and 47 from Purulia). Parasitic DNA was extracted followed by polymerase chain reaction and 
sequencing of different codons of pvdhfr gene (15, 33, 50, 57, 58, 61, 64, 117, and 173 codons) and pvdhps gene (373, 
380, 382, 383, 384, 512, 553, 585, and 601 codons) were performed to identify the mutations.
Results: Prevalence of double mutant dhfr A15P33N50F57R58T61V64N117I173 allele (53.85 %) was observed in Kolkata 
Municipal Corporation (KMC) whereas in Purulia, wild dhfr A15P33N50F57S58T61V64S117I173 allele was predominated 
(48.94 %). In pvdhps gene a significant number of isolates (17.31 %) in KMC contained the double mutant S373E380S-
382G383P384K512G553V585M601 allele. pvdhfr and pvdhps combination haplotype revealed the emergence of quadruple 
(13.46 %) and quintuple (3.84 %) mutant allele in KMC, which might result in poor clinical response against antifolate 
drugs.
Conclusion: The study reveals that P. vivax parasites in rural Purulia may still be susceptible to SP but additional cau-
tion should be taken for treatment of vivax malaria in KMC to limit the blooming of quadruple and quintuple mutant 
allele in the remainder of the West Bengal, India.
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Background
Malaria has been the major public health problem for the 
past few decades in West Bengal, Eastern India where 
both Plasmodium falciparum and Plasmodium vivax 
are equally prevalent. In 2013, 0.88 million people were 
affected by malaria, and of them 0.46 million patients 
were P. falciparum positive and 0.42 million patients were 
affected by P. vivax infection [1]. Although P. falciparum 
is the most deadly infection resulting in malignant malaria 
globally, P. vivax is the most widespread species in South-
east Asia, including India, causing severity and morbidity 
[2–5]. In 2009, artesunate plus sulfadoxine–pyrimeth-
amine (SP) combination was recommended as the first-
line drug against uncomplicated falciparum malaria, while 
chloroquine along with primaquine remains the first-line 
drug against vivax malaria in India [6]. The persistence of 
vast numbers of mixed P. falciparum and P. vivax infec-
tion in India is one of the major disease burdens as it is 
not easily discriminated by microscopy or rapid diagnos-
tic test kits (RDTs). Consequently a large proportion of P. 
vivax parasites are often involuntarily exposed to SP drug 
pressure, resulting in the evolution of SP-resistant P. vivax 
parasites [7]. The target of pyrimethamine and sulfadox-
ine are respectively dihydrofolate reductase (DHFR) and 
dihydropteroate synthase (DHPS), two major proteins of 
the folate biosynthesis pathway of parasites [8, 9]. Poly-
morphisms surrounded by the genes that encode these 
active enzymes are the major factor in SP resistance. In 
the case of P. falciparum infection, SP resistance has been 
predominantly observed with the polymorphism of dihy-
drofolate reductase (dhfr) and dihydropteroate synthase 
(dhps) genes, throughout the globe [8–13]. Similarly, 
polymorphisms in pvdhfr and pvdhps genes are proven 
to be linked with antifolate resistance in P. vivax infec-
tion. Polymorphism in pvdhfr S58R and S117N are highly 
associated with pyrimethamine resistance; additional 
mutation in P33L, N50I, F57L, T61M, V64L, and I173L 
codons increases the degree of resistance, i.e., very high 
IC50 values for pyrimethamine [14–17]. Different field 
studies suggest that polymorphism at A383G and A553G 
of pvdhps gene are solely responsible for sulfadoxine 
resistance while additional mutations at S373T, E380K, 
S382A, P384L, K512E, V585G, and M601I codons confer 
higher levels of resistance [18, 19]. Predominance of pvd-
hfr codon S58R and S117N polymorphisms and pvdhps 
codon A383G mutation in clinical isolates was reported 
in studies, mainly from central, western, northern and 
south eastern regions of India [7, 20, 21], before the intro-
duction of a new national drug policy. Very few studies 
are initiated in this part of eastern India although West 
Bengal is a malaria-endemic zone [7]. In 2010, 1.6 million 
confirmed malaria cases were reported in India; 134,795 
patients were from West Bengal [1, 22].
In such settings, molecular markers involved in SP 
resistance in P. vivax infection need to be evaluated after 
5  years of a new national drug policy, help to under-
stand the current scenario of antifolate resistance in P. 
vivax, as both Plasmodium spp. are predominate in this 
part of India, resulting in a rapid admixture of parasite 
population with selection pressure of drug. Prevalence 
of double or triple pfdhfr (AI51CN108I or AI51R59N108I) 
and triple or quadruple pfdhps (A436G437E540AA or 
A436G437E540AT613) mutation was observed in early 2012 
and 2013, in the same study sites of West Bengal, India, 
which surpassed the antifolate resistant (both in  vitro 
and in  vivo) P. falciparum disease burden in West Ben-
gal, India. This alarming sign for malaria control might be 
due to population migration and probable admixture of 
different ethnic groups [10–12].
The present investigation aimed to assess polymor-
phisms of pvdhfr and pvdhps genes to identify the tempo-
ral pattern of antifolate resistance among field isolates of 
urban Kolkata Municipal Corporation (KMC) and rural 
Purulia. This study might also identify combinations of 
different mutations that may lead to different qualitative 
and quantitative multidrug-resistant phenotypes. This 
knowledge of haplotype variance of candidate gene is of 




Phenol: chloroform: isoamyl alcohol, chloroform: isoa-
myl alcohols, agarose, p-amino benzoic acid-free RPMI 
1640 were purchased from Himedia, India. Tris–Hcl, Tris 
buffer, potassium dihydrogen phosphate (KH2PO4), dipo-
tassium hydrogen phosphate (K2HPO4), ethylene diamine 
tetra acetate (EDTA), sodium bicarbonate (NaHCO3), 
sodium acetate, ammonium acetate, ethanol, boric acid, 
glacial acetic acid were procured from Merck Ltd, SRL 
Pvt, Ltd, Mumbai, India. Proteinases K, RNase A, ethid-
ium bromide were purchased from Sigma Chemical Co, 
USA. Chloroquine tablets were procured from Resochin: 
Bayer. Oligonucleotide primers were purchased from 
New England Biolabs, USA. PCR grade nucleotide mix-
ture, MgCl2, dNTPs and Taq DNA polymerase were 
purchased from Roche, USA. lambda exonuclease was 
purchased from Gibco-BRL Life Technologies, France. 
pLDH kit was purchased from Diatek, Kolkata, India. All 
other chemicals were purchased from Merck Ltd, Mum-
bai and were of the highest grade available.
Study area
This study was conducted from December 2013 to 
November 2014 in KMC and Purulia, two malaria-
endemic regions of West Bengal, India (Fig. 1). Kolkata is 
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the main commercial and financial hub of east and north-
east India, mainly comprised of service industries, 
business community members, industrial and manufac-
turing members of a high socio-economic status, whereas 
Purulia is a hilltop, rural, forest area, where the majority 
of the population are farmers and labourers with low 
socio-economic status. In 2010, KMC contributed the 
highest malaria incidences (96,693) as well as the highest 
slide-positive rate (SPR) (27.21 %), the majority (82,467) 
being P. vivax infection [1, 22]. The highest number of 
mixed P. falciparum  +  P. vivax co-infection (543) was 
reported from KMC region, whereas in Purulia, another 
malaria-endemic region, P. falciparum was prevalent 
(70.13 % of 4526 malaria-positive cases, 3174 cases of P. 
falciparum infection), with no P falciparum  +  P. vivax 
co-infection [22]. Details of epidemiological information 
on the study sites are reported elsewhere [22].
Selection of subjects
The criteria for selection to conduct the experiments 
included history of fever during previous 24  h; mono-
infection with P. vivax based on microscopic examina-
tion of Giemsa-stained thin and thick blood smears; an 
RDT based on detection of Plasmodium-specific lactate 
dehydrogenase (pLDH) (OptiMAL-DT) having parasite 
density of 1000–200,000 asexual parasites/µl blood; and 
no recent history of self-medication with anti-malarial 
drugs. 18S rRNA gene, pvcsp gene was amplified by 
Fig. 1 Graphical presentation of different study site with different combination genotype
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nested PCR to identify P. vivax infection and rule out 
other mixed species infection [23, 24]. Patients with signs 
and symptoms of severe, complicated malaria, preg-
nant and lactating women, infants (under 2  years old), 
and those with haematocrit  <20  %, were excluded [25]. 
Informed consent was taken from all the patients and 
consent of a guardian was taken for children. Experimen-
tal design and protocol of this study was duly approved 
by the Vidyasagar University ethical committee.
Sampling design
The sample size for the experiment was determined as 
described by Pal and colleagues [26], and by the stand-
ard formula (n  =  z2pq  d−2). The minimum estimated 
sample size for each year was 31 [(1.962 × 0.00720 × 0.9
928)/0.032)]. The calculation was based on the incidence 
of annual parasitological index (API) of malaria in India. 
In 2013 API was recorded as 0.72 by the National Vector 
Borne Disease Control Programme (NVBDCP) [1]. The 
desired precision (d) was 3, where, API value was serve 
as p, q = p − 1 and z = 1.96. A total of 52 patients from 
KMC and 47 patients from Purulia (age ranging from 3 to 
76 years) were included in this study. Plasmodium vivax-
positive patients received standard 10 mg/kg chloroquine 
(CQ) on days 1 and 2, 5 mg/kg CQ on day 3, and 0.25 mg/
kg primaquine daily for 14  days (primaquine is contra-
indicated in G6PD-deficient patients) under the super-
vision of Prof Amiya Kumar Hati (ex-Director School 
of Tropical Medicine, Kolkata) and his team, as recom-
mended by NVBDCP [6].
Separation of red blood cells
Two ml of venous blood was collected from each of 
patient in a vacutainer (BD Falcon) coated with an antico-
agulant (EDTA). Red blood cells (RBCs) were separated 
using Histopaque 1077 density gradient followed by 
centrifugation at 1450  rpm for 45  min at 4  °C. An ali-
quot of approximately 1 ml of RBC pellet was obtained. 
Finally, erythrocytes were washed three times in folate 
and p-amino benzoic acid-free RPMI 1640 medium and 
stored at −20 °C for further analysis [27].
Parasite DNA isolation
Parasite DNA was extracted from 1  ml (approximately) 
of infected RBC using the phenol–chloroform extraction 
method as described elsewhere [27]. After air drying, the 
extracted parasite DNA was re-suspended in TE buffer 
(10 mM Tris, 1 mM EDTA, pH 8.4) and stored at −20 °C 
until further use. Isolated DNA was quantified by 1.2 % 
agarose gel electrophoresis. The purity of the parasite 
DNA was checked spectrophotometrically by calculating 
the A260/A280 ratio where A280 values determine pro-
tein impurities.
Primer designing and PCR amplification of pvdhfr 
and pvdhps genes
Point mutations in different variants of pvdhfr and 
pvdhps genes were investigated in all P. vivax isolates by 
nested PCR reactions, followed by sequencing analysis. 
Primers were designed on the basis of complete P. vivax 
strain sequence (accession number X98123 for pfdhfr 
and AY186730 for pvdhps) available in the GenBank. 
Approximately 200 ng of genomic parasite DNA, 10 pmol 
of primers, 1X reaction buffer (10 mM Tris, 50 mM KCl, 
pH 8.4), 2.7  mM MgCl2, 150  μM dNTPs, and 1 unit of 
Taq DNA polymerase were used to prepare 25  μl reac-
tion mixture (master mix). PCR cycle conditions were 
varied in different genes. Detailed primer sequence and 
cycle conditions are shown in Table 1. In nest-I reaction, 
pvdhfr gene was amplified by A1F and A1R primer pair 
Table 1 PCR primer sequences and reaction conditions were used for the amplification of sequences encoding Plasmo-
dium vivax dhfr and dhps gene
Gene Primer  
name




 pvdhfr A1F 5′ATGGAGGACCTTTCAGATGTATTTGACATT 3′ 720 105 °C for 5 min; (95 °C for 30 s; 50 °C for 30 s; 72 °C  
for 50 s) × 30 cycles; 72 °C for 10 minA1R 5′GGCGGCCATCTCCATGGTTATTTTATCGTG 3′
 pvdhps 2A F 5′ATTCCAGAGTATAAGCACAGCACATTTGAG3′ 840 104 °C for 5 min; (95 °C for 50 s; 57 °C for 1 min; 72 °C  
for 1 min) × 35 cycles; 72 °C for 10 min2A R 5′CTAAGGTTGATGTATCCTTGTGAGCACATC 3′
Nest II
 pvdhfr A2F 5′TTTATGATGGAACAAGACTGGGACGTT 3′ 701 100 °C for 5 min; (95 °C for 45 s; 52 °C for 40 s; 72 °C for 
1 min) × 32 cycles; 72 °C for 10 minA2R 5′TCACACGGGTAGGCGCCGTTGATCCTCGTG 3′
 pvdhps 2 B F 5′AATGGCAAGTGATGGGGCGAGCGTGATT 3′ 610 95 °C for 5 min; (94 °C for 40 s; 54 °C for 55 s; 72 °C for 
1 min) × 35 cycles; 72 °C for 10 min2B R 5′CAGTCTGCACTCCCCGATGGCCGCGCCAC 3′
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whereas 2A F and 2A R primer was used to amplify the 
pvdhps gene. The amplicon produced by NEST I reac-
tion was used as the template DNA in NEST II reac-
tion. All PCR amplifications contained a positive control 
(genomic DNA from quality control 3D7 strain) and a 
negative control (no target DNA).
DNA sequencing of pvdhfr and pvdhps genes
After adequate PCR amplification of different ampli-
con, sequencing reactions were carried out in 3730xl 
genetic analyzer (Applied Biosystems)  ≥2× coverage 
using an ABI Prism Big Dye Terminator cycle sequenc-
ing ready reaction kit. In the sequencing PCR reaction 
the final master mix volume was 20 µl, consisting of 1 µl 
of Terminator ready reaction mix (TRR), 3.2  pmol of 
gene-specific primer, and 0.5× sequencing buffer [28]. 
Sequencing experiments were carried out at the Indian 
Institute of Technology, Kharagpur (IIT, Kharagpur), and 
Sci Genome Company (Kochin). Electrophoregrams were 
visualized and analysed with CEQ 2000 genetic analysis 
system software (Beckman Coulter), and the sequenc-
ing traits were translated in the translation tool, available 
online at the Expert Protein Analysis System proteomic 
server [28]. Translated sequences were aligned online 
by the multiple sequence alignment tool ClustalW2 [28] 
and compared with the wild-type allele sequences (Gen-
Bank accession numbers, X98123 for pvdhfr, AY186730 
for pvdhps). Polymorphisms of these two genes were con-
firmed by reading both the forward and reverse strands.
Statistical analysis
The data were expressed as median ±  SD values and  % 
(percentage) variation; 95  % confidence intervals 
were calculated using Clopper-Pearson exact method. 
Graphical presentation of dhfr and dhps gene was carried 
out in Statistical Package, Origin 6.1.
Results
Polymorphism of pvdhfr gene
Monoclonal P. vivax infection was confirmed after allelic 
family-specific nested-PCR. A total of 99 P. vivax-posi-
tive patients confirmed by microscopy and PCR were 
recruited into the study population. The entire DHFR 
domain of pvdhfr gene was successfully sequenced in all 
99 clinical P. vivax isolates. Predominance of wild type 
dhfr allele (n  =  23, 48.94  %) was observed in Purulia 
whereas only 19 (36.54  %) isolates contained wild dhfr 
allele in KMC. Among these isolates, mutations were 
absent in codons 15, 33, 50, 61, 64, and 173. The fre-
quency of non-synonymous polymorphism at S58R 
and S117N was higher among the isolates. In KMC 
63.46  % of isolates presented mutant S58R codon, fol-
lowed by mutant S117N codon (57.69  %) and F57L 
codon (3.84  %). Like KMC, polymorphism at codon 
S58R (42.55  %) was most prevalent in Purulia, followed 
by S117N polymorphism (36.17 %) (Fig. 2). Beside these 
known non-synonymous polymorphisms, three synony-
mous mutations at G38G {GGT → GGG; in five isolates 
(7.69 %)}, Y69Y {TAT → TAC; in three isolates (5.77 %)} 
and V134  V  {GTC  →  GTT, in one isolate (1.92  %)} 
codon were identified in KMC. On the contrary in 
Purulia, a single synonymous mutation at E119E codon 
{GAG → GAA, in three isolates (6.38 %)} was observed.
Mutation assessment of pvdhps gene
Different variant of pvdhps gene flanking was success-
fully amplified and sequenced in all 52 patients from 
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Fig. 2 Frequency (% percentage) of different pvdhfr and pvdhps genotype
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non-synonymous and two synonymous mutations were 
found in the study site. Non-synonymous mutation at 
codon A383G was most prevalent (61.54  %) in KMC, 
followed by A553G mutation (17.30  %). pfdhps A383G 
polymorphism was far lower in Purulia. Only 21.27  % 
of isolates presented the mutant A383G allele fol-
lowed by A553G mutant allele (12.77 %). Another non- 
synonymous mutation at P384L codon (6.38  %) was 
observed in Purulia (Fig. 2). No mutation was observed 
at codons S373T, E380K, S382A, K512E, V585G, and 
M601I. Beside these non-synonymous polymorphisms, 
two synonymous mutations were identified at R487R 
codon {CGC  →  CGG; in two isolates (3.85  %)}, and 
L600L {CTA → CTG; in three isolates (6.38 %)} codon 
in KMC. No synonymous mutation was identified in 
Purulia.
Regional distribution of pvdhfr and pvdhps haplotype
Four different pvdhfr haplotypes were identified in 
KMC as well as in Purulia. In KMC, double mutant 
dhfr A15P33N50F57R58T61V64N117I173 allele (53.85  %) was 
frequently found after wild type A15P33N50F57S58T61 
V64S117I173 haplotype (36.54  %). In Purulia, wild type 
A15P33N50F57S58T61V64S117I173 allele was commonly 
(48.94 %) observed pvdhfr haplotype, followed by double 
mutant A15P33N50F57R58T61V64N117I17 allele (27.66  %). 
In KMC only 5.77  % of isolates represented pvdhfr sin-
gle mutant A15P33N50F57R58T61V64 S117I173 allele whereas 
14.89  % isolates in Purulia contained this single mutant 
allele. Interestingly, 8.51 % of isolates presented the single 
mutant S117 N codon, i.e., A15P33N50F57S58T61V64N117I173 
allele in Purulia. In Purulia, 23.40 % of isolates contained 
single pvdhfr mutation which was far higher than KMC 
(Table  3). In KMC, triple mutant A15P33N50L57R58T61 
V64N117I173 allele was found in 3.84 % of isolates. No iso-
late was found to contain quadruple or quintuple pvdhfr 
mutations (Fig. 3).
In the case of pvdhps gene, three different haplotypes 
(wild type, 383G, 383G + 553G) were identified in KMC 
and four different haplotypes (wild type, 383G, 553G, 
384L) in Purulia. Single mutant pvdhps S373E380S382 
G383P384K512A553V585M601 haplotype (44.23  %) was 
most predominant haplotype in KMC, followed by wild 
type pvdhps S373E380S382A383P384K512A553V585M601 allele 
(38.46  %). To the contrary, in Purulia, wild type pvdhps 
S373E380S382A383P384K512A553V585M601 allele (59.57 %) was 
highly prevalent pvdhps haplotype after single mutant 
pvdhps S373E380S382G383P384K512A553V585M601 allele 
(21.27 %). Interestingly, 17.31 % of isolates in KMC had 
represented the double mutant S373E380S382G383P384K512 
G553V585M601 allele but it was absent in isolates collected 
from Purulia (Fig. 3; Table 3).
Variation and distribution of different tandem repeat
Two different tandem repeat variants were found, 
depending on deletion/insertion of six amino acids 
(GDNTSG) at pvdhfr gene. The type 2 tandem repeat of 
pvdhfr gene was the most common repeat polymorph 
observed in KMC (80.77 %) as well as in Purulia (100 %). 
Monomorphic tandem repeat variant was observed in 
Purulia, whereas polymorphic tandem repeats were 
found in isolates of KMC.
In pvdhps gene, three different tandem repeats variants 
were identified on the basis of deletion/insertion of seven 
amino acid repeat (GEAKLTN). Type B tandem repeat 
of pvdhps gene was prevalent in the study site in KMC 
(89.36  %) as well as in Purulia (63.47  %). Two tandem 
repeats were identified in isolates from KMC and three 
in Purulia. Distribution of tandem repeat variants in the 
study sites are presented in Table 2.
Combination mutation of pvdhfr and pvdhps gene 
and emergence of quadruple and quintuple mutant allele
A total of ten different pvdhfr–pvdhps two-locus hap-
lotype combinations were identified among the total 99 
isolates (Fig. 3). Seven different pvdhfr–pvdhps haplotype 
combinations (G1, G2, G3, G5, G6, G7, G10) were found 
in KMC and eight different haplotype combinations (G1, 
G2, G3, G4, G5, G6, G8, G9) were observed in Purulia 
(Table 3). Eleven isolates (21.15 %) in KMC and 17 isolates 
(36.17 %) in Purulia respectively presented the wild type 
two-locus genotypes, i.e., G1 genotype. A large number of 
isolates (28.84 % of isolates in KMC and 14.89 % of isolates 
in Purulia) had represented the double mutant pvdhfr and 
single mutant pvdhps (G6) allele. Haplotype data revealed 



















































































































Fig. 3 Frequency (% percentage) of different pvdhfr–pvdhps haplo-
type sequences in KMC and Purulia
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that pvdhfr–pvdhps combination mutation begun to 
increase in number in KMC compared to Purulia. Some 
13.46  % of isolates in KMC contained double mutation 
in both pvdhfr and pvdhps (G7) gene (quadruple muta-
tion in two-locus combinations) but this haplotype was 
not observed in Purulia. Interestingly, in KMC, a very low 
proportion of quintuple mutation in two-locus combina-
tion (G10 genotype, triple mutation in dhfr gene and dou-
ble mutation in dhps gene) was observed in 3.84 % (n = 2) 
of isolates but this haplotype was absent in isolates of 
Purulia (Table 3).
Discussion
Genetic diversity in Plasmodium is well known in India 
as both P. falciparum and P. vivax are prevalent in the 
same ecological niche. As P. falciparum and P. vivax 
parasites co-exist in this region and both have the same 
drug target against antifolate drug [7–11], the risk of 
resistance development is high. Polymorphisms in differ-
ent variants of pvdhfr and pvdhps genes were known to 
be associated with antifolate resistance [8, 9]. However, 
mathematical modelling, in vitro experiments, and tran-
scriptomic studies all suggest that reduced susceptibility 
to SP is solely related to pvdhfr and pvdhps [8, 13, 15, 19]. 
Therefore, genotyping of these candidate gene markers of 
P. vivax may elucidate trends of SP resistance in India.
The predominance of pvdhfr double mutant 
58R +  117N (53.84  % in KMC and 27.65  % in Purulia) 
polymorphism was observed followed by single mutant 
S58R and S117N mutation. Non-synonymous 57L muta-
tion was detected in combination with 58R  +  117N in 
low frequency (3.85  %). These findings were similar to 
those reported from different parts of India [7, 20], Paki-
stan [29, 30], Afghanistan [31], China [32], Nepal [33], 
Thailand [18, 34, 35], and Indonesia [36]. In the study 
did not identify any polymorphism at codons A15, P33L, 
N50I, T61M, V64L, and I173L of pvdhfr gene, as previ-
ously reported from different parts of India [20, 22, 37]. It 
was postulated that pvdhfr S117N mutation might occur 
first, followed by the S58R mutation. Polymorphisms at 
codons F57L and T61M might take place independently 
with an increase in drug pressure [14]. The triple 
(L57R58N117) and quadruple (L57R58M61N117) pvdhfr poly-
morphism possessed progressive tolerance in P. vivax to 
SP, thus these genotypes were associated with high risk 
of therapeutic SP failure [35]. Unlike previous reports in 
India [20, 21], no quadruple mutation was observed in 
study site, although only two isolates (3.85  %) in KMC 
had represented the triple mutant allele, which was previ-
ously not observed in KMC [7].
Different studies from various geographical locations 
imply that polymorphism of dhfr gene was associated 
with tandem repeat polymorphism. In the study, it was 
observed that predominance of double dhfr mutation 
was associated with type-2 tandem repeat variant, which 
strongly supported the previous report in India [21]. On 
the contrary, previous reports from different geographi-
cal regions suggested that type-1 tandem repeat variant 
was highly associated with triple or quadruple mutant 
dhfr alleles [17, 21]. Similarly, not a single type-1 tandem 
repeat was identified in Purulia where no triple or quad-
ruple mutations were observed, although a single excep-
tion to this was previously observed in Myanmar [38]. In 
the case of dhps gene, type B tandem repeat was preva-
lent in KMC as well as in Purulia, which was previously 
reported in different parts of India and Pakistan [29, 
39]. Previous genome-wide analysis suggested that the 
type B tandem repeat was generally associated with wild 
type pvdhps gene, as happened in the study site, whereas 
the existence of double mutant pvdhps (383G  +  553G) 
haplotype was generally associated with type A tandem 
repeat [29, 39]. Thus, the tandem repeat could be used as 
a molecular marker to predict the risk mutant genotypes 
that confer higher level resistance.
Polymorphism in dhps gene was higher in KMC than in 
Purulia isolates but there were some similarities in both 
places. In the case of pvdhps gene, polymorphisms were 
mainly observed at codons A383G and A553G. Unlike 
a previous report from KMC [7], double dhps mutation 
at 383G +  553G was predominantly observed in KMC. 
Absence of double dhps mutation (A383G + A553G) in 
Purulia indicated about there was less drug pressure of 
Table 2 Region wise distribution of tandem repeat variants of DHFR and DHPS gene
Gene Type Tandem repeat KMC (%) Purulia (%)
Dhfr Type 1 GDNTSGGDNTHGGDNTHGGDNADKL 19.23 0.00
Type 2 GDNTSGGDNTHG------------GDNADKL 80.77 100
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SP, in contrast to KMC. Predominance of double dhps 
383G  +  553G mutations were previously observed in 
isolates from Asaam, Nadiad and Tamil Nadu [20, 21]. 
It now proved that polymorphism at A383G and A553G 
were solely responsible for sulfadoxine resistance in vitro 
as well as in vivo as they possessed the sulfadoxine bind-
ing site in dhps gene, additional mutations at E380  K, 
S382A, P384L, K512E, V585G, and M601I codons confer 
higher levels of sulfadoxine resistance [18, 19].
In case of combination mutation of pvdhfr and pvdhps 
gene, it was clearly observed that the proportion of triple 
mutation (R58N117–G383), quadruple mutation (R58N117–
G383G553), and quintuple mutation (L57R58N117–G383G553) 
were higher in KMC than Purulia. The probability for 
these major variations might be embedded in the basis 
of geographical variations of parasite infection. It was 
reported that P. falciparum +  P. vivax mixed infection 
was highest in KMC whereas not a single case of P. fal-
ciparum  +  P. vivax mixed infection was observed in 
Purulia [22]. Thus, the parasite from KMC might pos-
sess higher SP partial pressure than those isolates from 
Purulia. Secondly, KMC was the gateway to Southeast 
Asia in India and the mixed population was very high in 
that part of India, which might produce westward move-
ment of CQ and SP-resistant parasites from Greater 
Mekong Sub-region to Africa through India [40, 41].
In India, SP was never prescribed against P. vivax [7]; 
the emergence of point mutations in pvdhfr and pvdhps 
genes was quite unexpected. Exposure of P. vivax to SP 
might arise due to several reasons: first, P. falciparum and 
P. vivax mixed infections were very common here; artesu-
nate plus SP was generally recommended in those patients 
and thus, P. vivax parasites may be directly exposed to SP 
drug pressure. In the study site, the proportion of P. falci-
parum isolates with increased pfdhfr and pfdhps polymor-
phisms has been identified over the past decade [10–12]. 
The increase in the number of P. falciparum +  P. vivax 
co-infection might exert some selection pressure of SP 
over the P. vivax population; secondly, there could be a 
situation where a clinician recommended an anti-malar-
ial drug depending upon the clinical grounds but with a 
lack of immediate diagnosis, as well as erroneous diag-
nosis of the parasite species; thirdly, presumptive treat-
ment of malaria without proper diagnosis and use of SP 
combination by private practitioners could not be ruled 
out [21, 34]. Emergence and subsequent spread of multi-
drug-resistant parasites is a problem for malaria control 
and elimination programme. It is essential to identify and 
assess drug resistance markers in a regular, synchronous 
manner to recognize drug-resistant areas on the basis of 
candidate gene polymorphism analysis, which ultimately 
helps to manage suitable anti-malarial drug policy.
Conclusion
The findings suggest that P. vivax parasites in rural Purulia 
may still be susceptible to SP, but additional caution 
should be taken for treatment of vivax malaria in KMC 
to limit blooming of quadruple and quintuple mutant 
allele in the remainder of West Bengal, India. Synchro-
nized research, surveillance and containment strategies 
are essential to optimize the current use of anti-malarial 
drugs to limit resistance and to understand the proper 
genetic lineage of resistant parasites.
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